Literature DB >> 11093436

Activity indices in rheumatoid arthritis.

V Villaverde1, A Balsa, M Cantalejo, M Fernández-Prada, M R Madero, S Muñoz-Fernández, J Gijón-Baños, E Martín-Mola.   

Abstract

OBJECTIVE: To determine which activity indices better correlate with assessor's (AGA) and patient's (PGA) global assessment of disease activity and to compare the improvement with American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria and their association with PGA and AGA of overall improvement.
METHODS: Seventy-five patients with rheumatoid arthritis (RA) were studied. Swollen and tender joints, morning stiffness, grip strength, pain, AGA, PGA, Health Assessment Questionnaire (HAQ) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CPR), and hemoglobin were determined before and 6 months after treatment. Several activity indices were calculated: Disease Activity Score (DAS), DAS 3, DAS 28, DAS '28,' ACR > or = 20%, Mallya, Riel, IDA, and a modification of the Stoke index.
RESULTS: All indices correlated with PGA and AGA before and after treatment (r > 0.38, p < 0.01), but better results were obtained with AGA than PGA. DAS, DAS 3, DAS 28, and modified Stoke had the best correlation with AGA (r > or = 0.77, p < 0.01). The indices that better detected the differences after treatment for AGA were DAS, DAS 3, DAS 28, and modified Stoke (r > or = -0.42, p < 0.01). The level of agreement between EULAR and ACR improvement classifications with both reduced and extensive joint counts was comparable and its association with PGA and AGA overall improvement was significant (p < 0.01).
CONCLUSION: All activity indices correlated with PGA and AGA, although the best results were obtained with AGA. Although indices' correlations were similar, the DAS group and the modified Stoke seemed to be the most useful indices to measure disease activity in RA. The discriminating potential between ACR and EULAR improvement classification was comparable, as was the association with PGA and AGA overall improvement.

Entities:  

Mesh:

Year:  2000        PMID: 11093436

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells.

Authors:  S W Tas; P Quartier; M Botto; L Fossati-Jimack
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Relationship between high-resolution computed tomography findings and the Stoke index in patients with rheumatoid arthritis.

Authors:  Meryem Saracoglu; Baris Nacir; Nurgul Arinci Incel; Hakan Genc; Hatice Rana Erdem
Journal:  Clin Rheumatol       Date:  2004-08-24       Impact factor: 2.980

3.  When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

Authors:  M Dougados; P Emery; E M Lemmel; C A F Zerbini; S Brin; P van Riel
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103

4.  Effects of 15 consecutive cryotherapy sessions on the clinical output of fibromyalgic patients.

Authors:  Lorenzo Bettoni; Felice Giulio Bonomi; Viviana Zani; Luigia Manisco; Annamaria Indelicato; Patrizia Lanteri; Giuseppe Banfi; Giovanni Lombardi
Journal:  Clin Rheumatol       Date:  2013-05-02       Impact factor: 2.980

5.  Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).

Authors:  Hidehisa Saeki; Hidemi Nakagawa; Ko Nakajo; Taeko Ishii; Yoji Morisaki; Takehiro Aoki; Gregory S Cameron; Olawale O Osuntokun
Journal:  J Dermatol       Date:  2016-10-11       Impact factor: 4.005

6.  Tumour necrosis factor gene polymorphisms in Egyptian patients with rheumatoid arthritis and their relation to disease activity and severity.

Authors:  Heba M Zaghlol; Sanaa Abdelshafy; Rabab A Mohamed; Enas A Abdelaleem
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

7.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

8.  Foot problems in a group of patients with rheumatoid arthritis: an unmet need for foot care.

Authors:  Pinar Borman; Figen Ayhan; Figen Tuncay; Mehtap Sahin
Journal:  Open Rheumatol J       Date:  2012-10-04

9.  Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Authors:  Xin Zhang; Laiyi Chua; Charles Ernest; William Macias; Terence Rooney; Lai San Tham
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-10-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.